Tags

Type your tag names separated by a space and hit enter

An assessment by the Statin Diabetes Safety Task Force: 2014 update.
J Clin Lipidol 2014 May-Jun; 8(3 Suppl):S17-29JC

Abstract

Statin therapy reduces the risk of myocardial infarction, stroke, and cardiovascular death by 25% to 30% in primary as well as secondary prevention patients. Thus, statins are the pharmacologic therapy of choice for the management of high blood cholesterol levels. Prompted by examination of clinical trial data suggesting a modest, but statistically significant, increase in the incidence of new-onset type 2 diabetes mellitus with statin use, the US Food and Drug Administration in 2012 added a statement to the labels of statin medications indicating that increases in glycated hemoglobin (HbA1C) and fasting glucose levels have been reported with statin use. This labeling change has raised questions among clinicians regarding the relative benefits and risks of statin use, both among patients with diabetes mellitus and among those with diabetes risk factors. This 2014 report from the Diabetes Subpanel of the National Lipid Association Expert Panel on Statin Safety reviews the published evidence relating statin use to the hazard for diabetes mellitus or worsening glycemia, examines potential mechanisms that may mediate the relationship between statin use and diabetes mellitus risk, and suggests future research efforts. Given the well-established benefits of statin therapy in the primary and secondary prevention of cardiovascular events among those with indications for treatment, no changes to clinical practice are recommended other than the measurement of HbA1C or fasting glucose in those deemed to also be at elevated diabetes risk after initiating statin therapy, and potentially before initiation in selected patients considered to be at elevated risk of developing diabetes. The panel advocates following recommendations from the American Diabetes Association, or other relevant guidelines if outside the United States, for screening and diagnosis as well as lifestyle modification for prevention or delay of diabetes mellitus in those with prediabetes or other risk factors.

Authors+Show Affiliations

Midwest Center for Metabolic & Cardiovascular Research and DePaul University, 6323 North Avondale Avenue, Suite 103, Chicago, IL 60631, USA. Electronic address: kmaki@mc-mcr.com.Brigham and Women's Hospital and the Harvard Medical School, Boston, MA, USA.Emory University School of Medicine, Atlanta, GA, USA.The University of Texas Southwestern Medical Center, Dallas, TX, USA.University of Glasgow, Glasgow, UK.No affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

24793439

Citation

Maki, Kevin C., et al. "An Assessment By the Statin Diabetes Safety Task Force: 2014 Update." Journal of Clinical Lipidology, vol. 8, no. 3 Suppl, 2014, pp. S17-29.
Maki KC, Ridker PM, Brown WV, et al. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S17-29.
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., Sattar, N., & The Diabetes Subpanel of the National Lipid Association Expert Panel, . (2014). An assessment by the Statin Diabetes Safety Task Force: 2014 update. Journal of Clinical Lipidology, 8(3 Suppl), pp. S17-29. doi:10.1016/j.jacl.2014.02.012.
Maki KC, et al. An Assessment By the Statin Diabetes Safety Task Force: 2014 Update. J Clin Lipidol. 2014;8(3 Suppl):S17-29. PubMed PMID: 24793439.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An assessment by the Statin Diabetes Safety Task Force: 2014 update. AU - Maki,Kevin C, AU - Ridker,Paul M, AU - Brown,W Virgil, AU - Grundy,Scott M, AU - Sattar,Naveed, AU - The Diabetes Subpanel of the National Lipid Association Expert Panel,, PY - 2014/02/27/received PY - 2014/02/28/accepted PY - 2014/5/6/entrez PY - 2014/5/6/pubmed PY - 2014/12/17/medline KW - Coronary heart disease KW - Lipid KW - National Lipid Association KW - Statin KW - Type 2 diabetes mellitus SP - S17 EP - 29 JF - Journal of clinical lipidology JO - J Clin Lipidol VL - 8 IS - 3 Suppl N2 - Statin therapy reduces the risk of myocardial infarction, stroke, and cardiovascular death by 25% to 30% in primary as well as secondary prevention patients. Thus, statins are the pharmacologic therapy of choice for the management of high blood cholesterol levels. Prompted by examination of clinical trial data suggesting a modest, but statistically significant, increase in the incidence of new-onset type 2 diabetes mellitus with statin use, the US Food and Drug Administration in 2012 added a statement to the labels of statin medications indicating that increases in glycated hemoglobin (HbA1C) and fasting glucose levels have been reported with statin use. This labeling change has raised questions among clinicians regarding the relative benefits and risks of statin use, both among patients with diabetes mellitus and among those with diabetes risk factors. This 2014 report from the Diabetes Subpanel of the National Lipid Association Expert Panel on Statin Safety reviews the published evidence relating statin use to the hazard for diabetes mellitus or worsening glycemia, examines potential mechanisms that may mediate the relationship between statin use and diabetes mellitus risk, and suggests future research efforts. Given the well-established benefits of statin therapy in the primary and secondary prevention of cardiovascular events among those with indications for treatment, no changes to clinical practice are recommended other than the measurement of HbA1C or fasting glucose in those deemed to also be at elevated diabetes risk after initiating statin therapy, and potentially before initiation in selected patients considered to be at elevated risk of developing diabetes. The panel advocates following recommendations from the American Diabetes Association, or other relevant guidelines if outside the United States, for screening and diagnosis as well as lifestyle modification for prevention or delay of diabetes mellitus in those with prediabetes or other risk factors. SN - 1933-2874 UR - https://www.unboundmedicine.com/medline/citation/24793439/An_assessment_by_the_Statin_Diabetes_Safety_Task_Force:_2014_update_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1933-2874(14)00074-9 DB - PRIME DP - Unbound Medicine ER -